1                                                             We categorised all uncommon mutations as: point mutations or

2                                                             We categorised complications as severe or non-severe.

3                                                             We categorised deaths based on VDC weapon type.

4                                                             We categorised interventions as those seeking to increase dem

5                                                             We categorised participants as HIV negative, known HIV infect

6                                                             We categorised studies and funding by disease, cross-cutting

7                                                             We categorised studies on the basis of the JPIAMR strategic r

8                                                    Finally, we categorised the localisation of the membranous/cortical pr

9 e effectiveness against single antigens (G-type or P-type), we categorised them as either single-antigen vaccine type or